Compare iShares Core High Dividend ETF (HDV) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Revvity Inc — how do they compare? iShares Core High Dividend ETF trades at $28.99, while Revvity Inc trades at $115.23 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while iShares Core High Dividend ETF pays none. Which is the better fit depends on your goals.
| HDV | RVTY | |
|---|---|---|
52-Week High | $29.14 | $117.75 |
52-Week Low | $23.64 | $82.26 |
Market Cap | — | $12.91B |
Sector | — | Technology |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV trades at $28.92, down 0.24% on the day, with a bullish technical signal supported by moving averages. The ETF focuses on high-quality dividend stocks, offering a 3.1% yield and outperforming the S&P 500 year-to-date by 9 percentage points according to 24/7 Wall Street on July 23, 2026. Recent institutional buying includes Bay Colony Advisory Group increasing its position by 370.7% in Q2 2026.
The outlook remains positive for income investors seeking stable dividends from large-cap US companies. Key risks include interest rate sensitivity and sector concentration in defensive stocks. Institutional accumulation and strong technical momentum support continued investor interest in this dividend-focused ETF.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
